Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Array BioPharma, a biopharmaceutical company, has reported positive preclinical data of a novel small molecule glucokinase activator, ARRY-403, a drug for the treatment of Type 2 diabetes.
Subscribe to our email newsletter
The data showed that in multiple well-established in vivo models of Type 2 diabetes, ARRY-403 was highly efficacious in controlling both fasting and non-fasting glucose, with rapid onset of effect and maximal efficacy within five to eight days.
In combination with existing standard-of-care drugs (metformin, DPP4 inhibitor) ARRY-403 provided additional glucose-control, which reached maximal efficacy after five to seven days of once-daily dosing, the company said.
Based on these and other results, Array plans to advance ARRY-403 into human clinical studies in the first half of 2009.
Kevin Koch, president and chief scientific officer of Array BioPharma, said: “There is a significant need for new, more effective oral diabetes treatments – and glucokinase activation represents a promising new mechanism. Glucokinase activators hold the potential to bring a significant benefit to Type 2 diabetes patients and we believe ARRY-403 is a highly potent and safe glucokinase activator.”